Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690875 | 0.88 | ALDH1A1 (0.66) | NCF1HRH3PSMB8KDM4EALDH1A1 | |
| SCHEMBL3149449 | 0.86 | NCF1 (0.55) | NCF1HRH3PSMB8KDM4EALDH1A1 | |
| SCHEMBL3141635 | 0.86 | SIGMAR1 (0.51) | NCF1HRH3PSMB8CNR1NPC1 | |
| SCHEMBL3133105 | 0.83 | SIGMAR1 (0.58) | HRH3HTTCNR1DRD2 | |
| SCHEMBL3133899 | 0.83 | HRH3 (0.79) | HRH3ALDH1A1HPGDNOS1CYP2D6 | |
| SCHEMBL24061140 | 0.82 | HRH3 (0.58) | NCF1HRH3PSMB8KDM4EALDH1A1 | |
| SCHEMBL3146310 | 0.82 | MC4R (0.54) | HRH3DRD2HTR1ADRD4DRD3 | |
| SCHEMBL11196105 | 0.81 | NCF1 (0.83) | NCF1HRH3PSMB8KDM4EALDH1A1 | |
| SCHEMBL16378748 | 0.79 | HRH3 (0.54) | NCF1HRH3PSMB8KDM4EALDH1A1 | |
| SCHEMBL26378178 | 0.79 | KCNH2 (0.54) | NCF1HRH3PSMB8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| EP-3781159-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781557-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3773554-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200261418-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2020-08-20 | — | — | US | disclosed |
| CN-111432884-A | Combination of HDAC inhibitors with immune checkpoint modulators for cancer therapy | 4SC股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3678740-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019197682-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019185598-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019048629-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-14 | — | — | WO | disclosed |
| US-8815855-B2 | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | 4SC AG (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | MAIER THOMAS | 2010-03-25 | — | — | US | disclosed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | NCF1 2310/4885HRH3 79/4885PSMB8 221/4885 |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | HDAC1, H1-3, HDAC2 | NCF1 917/4885HRH3 57/4885PSMB8 2127/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | NCF1 641/4885HRH3 318/4885PSMB8 2022/4885 |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | NCF1 1043/4885HRH3 110/4885PSMB8 1255/4885 |
| US-20200261418-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | HDAC4, HDAC5, HDAC9 | NCF1 1465/4885HRH3 372/4885PSMB8 1412/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | NCF1 1332/4885HRH3 273/4885PSMB8 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.